Pricing Log in Create free account
Saturday 31 October 2026 Export ABBV’s income statement to Excel — free account

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

294.90 4.11 +1.41%
Market cap
$513.9B
P/E
83.3×
Fwd P/E
38.6×
Dividend yield
2.35%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

AbbVie Inc. 10-Q filed May 8, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 12:28 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov